Physician profile
Gregory Walker
NPI 1487074084
$12,029.50
in general payments reported to CMS, 2019-2025
40 companies · $3,119 in 2025
The $3,119 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $795 · 2020: $296 · 2021: $670 · 2022: $2,234 · 2023: $2,353 · 2024: $2,562 · 2025: $3,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,000 · Education: $33.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,000.21 |
| Education | $33.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,809.11 | 2019-2025 | Rinvoq, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $1,063.93 | 2019-2025 | Dupixent, Libtayo |
| Pfizer INC. | $1,003.10 | 2019-2025 | |
| Janssen Biotech, INC. | $932.33 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Lilly USA, LLC | $753.84 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $678.62 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $626.10 | 2019-2025 | |
| Ucb, INC. | $535.45 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $526.44 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $459.59 | 2019-2025 | Winlevi, Absorica Ld, Odomzo |
| Incyte Corporation | $447.55 | 2023-2025 | Opzelura |
| Galderma Laboratories, L.P. | $410.11 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Leo Pharma INC. | $382.30 | 2022-2025 | Adbry |
| Almirall LLC | $334.23 | 2019-2024 | Seysara |
| Arcutis Biotherapeutics, INC. | $287.07 | 2024-2025 | Zoryve |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hill Dermaceuticals, INC. | $275.30 | 2021-2023 | Tolak |
| Amgen INC. | $253.22 | 2022-2025 | Otezla, Otezla, Krystexxa |
| Dermavant Sciences, INC. | $243.66 | 2023-2024 | Vtama |
| Organon LLC | $127.03 | 2023-2025 | Vtama, Hadlima |
| Kerecis Limited | $123.70 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.50 | 2023-2024 | Cyltezo, Spevigo |
| Allergan, INC. | $113.12 | 2020 | |
| Mimedx Group, INC. | $68.50 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $57.46 | 2022 | |
| Genentech USA, INC. | $48.17 | 2019-2021 | |
| Dusa Pharmaceuticals, INC. | $44.40 | 2019 | |
| Sandoz INC. | $39.01 | 2023-2024 | Hyrimoz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.19 | 2023 | Arazlo, Duobrii |
| Cipher Pharmaceuticals US LLC | $32.50 | 2025 | Natroba, Spinosad |
| Springworks Therapeutics, INC. | $26.44 | 2025 | Gomekli |
| Mylan Pharmaceuticals INC. | $24.90 | 2019 | |
| Melinta Therapeutics, LLC | $21.78 | 2020 | |
| Journey Medical Corporation | $19.30 | 2022 | |
| Dermira, INC. | $16.87 | 2020 | |
| Botanix Sb INC | $16.79 | 2025 | Sofdra |
| Nobelpharma America, LLC | $16.13 | 2023 | |
| Mission Pharmacal Company | $14.63 | 2019 | |
| Fresenius Kabi USA, LLC | $14.37 | 2023 | Idacio |
| Biocon Biologics INC | $14.22 | 2024 | Hulio |
| Prugen, INC. Pharmaceuticals | $13.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.